慢性骨髄性白血病治療の世界市場：薬剤タイプ別（チロシンキナーゼ阻害剤、代謝拮抗剤、その他）、流通チャネル別、地域別－規模、シェア、展望、機会分析（2021年～2028年）

主要企業による薬剤の上市数の増加は、予測期間中の市場成長を促進すると予想されます。また、主要企業による戦略的提携などの無機的な成長戦略の増加も、市場の成長を促進すると予想されます。

当レポートでは、世界の慢性骨髄性白血病治療市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場の内訳：薬剤タイプ別
  • 市場の内訳：流通チャネル別
  • 市場の内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 重要な開発
• PEST分析
• 規制シナリオ
• パイプライン分析
• 新製品の発売/承認
• 疫学
• 市場動向

第4章 COVID-19影響分析

• 経済的影響
• COVID-19疫学
• COVID-19に対応する政府のイニシアチブ

第5章 世界の慢性骨髄性白血病治療市場：薬剤タイプ別（100万米ドル）（2017年～2028年）

• イントロダクション
• チロシンキナーゼ阻害剤
• 代謝拮抗剤
• その他

第6章 世界の慢性骨髄性白血病治療市場：流通チャネル別（100万米ドル）（2017年～2028年）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界の慢性骨髄性白血病治療市場：地域別（100万米ドル）（2017年～2028年）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• 企業プロファイル
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Innovent Biologics, Inc.
  • Viatris Inc.(Mylan NV)
  • Lupin
  • IL-YANG PHARM CO. LTD.
  • Million Health Pharmaceuticals
  • Celon Labs
• アナリストの見解

第9章 セクション

Chronic myeloid leukemia (CML) is a cancer that initiates in the blood-forming cells of the bone marrow and enters the blood. It increases the number of white blood cells in the blood. Chronic myeloid leukemia is also known as chronic myelogenous leukemia. Chronic myeloid leukemia (CML) occurs mostly in adults, and rarely in children. Chronic myeloid leukemia (CML) is detected after the blood test is performed.

Chronic myeloid leukemia symptoms includes:

• Bone pain
• Easy bleeding
• Fever
• Weight loss
• Excessive sweating during sleep

Market Dynamics

Increasing number of drug launches by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market during the forecast period. For instance, in September 2017, Mylan N.V., a pharmaceutical company, announced the launch of Imatinib Mesylate tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets. Moreover, Mesylate tablets are approved by US Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic eosinophilic leukemia or hypereosinophilic syndrome, chronic myelogenous leukemia, and others.

Increasing number of inorganic growth strategies such as strategic collaboration by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market. For instance, in July 2021, Innovent Biologics, Inc., a biopharmaceutical company, announced strategic collaboration with Ascentage Pharma, a biopharmaceutical company. Moreover, this collaboration includes the joint clinical development and commercialization of HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor in China. Olverembatinib is indicated for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP).

Key features of the study:

• This report provides an in-depth analysis of global chronic myeloid leukemia treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global chronic myeloid leukemia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs

• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation:

• Global Chronic Myeloid Leukemia Treatment Market, By Drug Type:
• Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
• Antimetabolites
• Others
• Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Chronic Myeloid Leukemia Treatment Market, By Region:
• North America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.S.
  • Canada
• Latin America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc. (Mylan N.V.)
• Lupin
• IL-YANG PHARM CO. LTD.
• Million Health Pharmaceuticals
• Celon Labs

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Development
• PEST Analysis
• Regulatory Scenario
• Pipeline Analysis
• New Product Launch/ Approval
• Epidemiology
• Market Trends

4. COVID - 19 Impact Analysis

• Economic Impact
• COVID-19 Epidemiology
• Government Initiatives to Combat COVID-19

5. Global Chronic Myeloid Leukemia Treatment Market, By Drug Type, 2017-2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
• Tyrosine Kinase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
• Antimetabolites
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Chronic Myeloid Leukemia Treatment Market, By Region, 2017 - 2028 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

8. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Novartis AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Takeda Pharmaceutical Company Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Innovent Biologics, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Viatris Inc. (Mylan N.V.)
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Lupin
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • IL-YANG PHARM CO. LTD.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Million Health Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Celon Labs
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us and Sales Contact